Cochrane偏倚风险评估工具2(RoB 2)与原始RoB:利弊之见
The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons.
作者信息
Nejadghaderi Seyed Aria, Balibegloo Maryam, Rezaei Nima
机构信息
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of Medical Sciences Kerman Iran.
Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN) Tehran Iran.
出版信息
Health Sci Rep. 2024 Jun 3;7(6):e2165. doi: 10.1002/hsr2.2165. eCollection 2024 Jun.
BACKGROUND AND AIMS
Critical appraisal or risk of bias assessment is a fundamental part of systematic reviews that clarifies the degree to which included research articles are qualified and reliable. Version 2 of the Cochrane tool for assessing the risk of bias in randomized trials (RoB 2), the updated version of the first tool, was released in 2019. Here, we have compared these two versions of Cochrane risk of bias assessment tools and highlighted the pros and cons of RoB 2.
METHODS
Statistical analysis and methodology is not applicable to this article as no new data were created or analyzed in this study.
RESULTS
The overall approach in RoB 2 is that by answering some signaling questions after the specification of results, effects of interest, and sources of information, an overall judgment for the quality of each study is reached. Accordingly, in the original version of the Cochrane RoB tool, the judgment can be in three different conclusions, including low, unclear, and high risk of bias. The most prominent difference in bias domains is the removal of "other bias" domain being replaced by "overall bias" judgment. Also, the most common presentation types of Cochrane risk of bias assessments are the "summary" and "graph" which are generated by Review Manager, web-based applications, or packages in R software.
CONCLUSION
The RoB 2 tool, compared to the original RoB, has improved and is the recommended version by the Cochrane Collaboration for quality assessment of randomized controlled trials. It is recommended to consider funding source, duration of follow-up, declaration of data availability, the status of baseline characteristics between groups, and sample size calculation methods in further revisions of the Cochrane risk of bias assessment tools.
背景与目的
批判性评价或偏倚风险评估是系统评价的一个基本组成部分,它阐明了纳入的研究文章的合格程度和可靠性。用于评估随机试验偏倚风险的Cochrane工具的第2版(RoB 2),即第一个工具的更新版本,于2019年发布。在此,我们比较了这两个版本的Cochrane偏倚风险评估工具,并突出了RoB 2的优缺点。
方法
由于本研究未创建或分析新数据,因此统计分析和方法不适用于本文。
结果
RoB 2的总体方法是,在明确结果、感兴趣的效应和信息来源后,通过回答一些信号问题,对每项研究的质量做出总体判断。因此,在Cochrane RoB工具的原始版本中,判断可以有三种不同的结论,包括低、不清楚和高偏倚风险。偏倚领域最显著的差异是删除了“其他偏倚”领域,代之以“总体偏倚”判断。此外,Cochrane偏倚风险评估最常见的呈现类型是由Review Manager、基于网络的应用程序或R软件包生成的“总结”和“图表”。
结论
与原始的RoB相比,RoB 2工具有所改进,是Cochrane协作网推荐用于随机对照试验质量评估的版本。建议在Cochrane偏倚风险评估工具的进一步修订中考虑资金来源、随访持续时间、数据可用性声明、组间基线特征状态和样本量计算方法。